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Human herpesvirus-6 (HHV-6) is a major cause of limbic encephalitis with a dismal 
prognosis after allogeneic hematopoietic stem cell transplantation (SCT). Since our 
previous trial of preemptive therapy with foscarnet sodium (PFA) failed to prevent 
HHV-6 encephalitis, we conducted a prospective study to examine the safety of 
prophylactic PFA administration and elucidate the changes in the plasma HHV-6 DNA 
levels in the early post-SCT period. Plasma HHV-6 DNA was measured thrice weekly 
from day 6. PFA, 90 mg/kg/day, was administered from days 7 to 21 after bone marrow 
or peripheral blood stem cell transplantation and to 25 after umbilical cord blood 
transplantation. Of the 10 patients enrolled, two dropped out of the study due to early 
death and a low glomerular filtration rate. Grade 3 or greater adverse events occurred in 
9 of the 10 prophylactic PFA patients and in 7 of the 10 control patients who had 
clinical backgrounds similar to the study subjects and underwent SCT during the same 
period. Neurological disorders developed in none of the study subjects but in 4 of the 10 
control patients, including 2 with HHV-6 encephalitis. HHV-6 reactivation occurred in 3 
of 10 study subjects. The prophylactic PFA regimen was thus safe and it may reduce the 
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Human herpesvirus-6 (HHV-6) is a major cause of limbic encephalitis with a dismal 
prognosis after allogeneic hematopoietic stem cell transplantation (allo-SCT) (1). It was 
previously a rare complication after conventional allo-SCT, however, the incidence has 
been increasing as the number of alternative grafts, such as umbilical cord blood 
transplantation (UCBT), has increased (2). Currently, foscarnet sodium 
(phosphonoformic acid, PFA) and ganciclovir (GCV) are available in Japan for the 
treatment of HHV-6 infection, and PFA is thought to be preferable during the early post 
SCT period because of its lower toxicity for bone marrow (BM) (3). We previously 
conducted a prospective multicenter study to assess the safety and efficacy of 
preemptive therapy with PFA for the prevention of HHV-6 encephalitis, because the 
safety of PFA administration during neutrophil engraftment had not been established in 
UCBT recipients (4). This study revealed the safety of PFA administration beginning 
around day 15 after SCT or later; however, this strategy could not entirely prevent 
HHV-6-induced encephalitis. Based on these findings, we have started to consider 
prophylactic administration of PFA, but the safety of PFA administration before 
neutrophil engraftment after SCT has not yet been examined. We therefore designed a 
prospective institutional study to assess the safety of PFA administration in the early 
5 
 
post-SCT period. We herein present data on a matched-pair analysis comparing the 
patients who received the prophylactic PFA administration with those who did not 
receive such PFA treatment. 
 
Patients and Methods 
Endpoint of this study 
This study was conducted primarily to assess the incidence of adverse events (AEs) 
associated with PFA administration in the early post-SCT period. The secondary 
endpoint was to follow the change of the amount of plasma HHV-6 DNA and to assess 
the efficacy of the prophylactic administration of PFA for the HHV-6 DNAemia. 
 
Study design 
Eligible patients were aged from 16 to 75 years with hematologic disorders refractory to 
conventional therapy and were considered to require allo-SCT from alternative grafts 
such as an HLA-mismatched relative, an unrelated donor, or UCBT due to the 
unavailability of an HLA-matched relative between February 2009 and March 2010 at 
Kanazawa University Hospital. The study was offered to all HCT recipients who met 
the inclusion criteria, and the patients who agreed to join this study were enrolled. 
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Written informed consent was obtained from all subjects according to the Declaration of 
Helsinki, and this study protocol was approved by the institutional ethics committee 
(#5537). This trial was registered in the UMIN Clinical Trials Registry (UMIN-CTR; 
http://www.umin.ac.jp/ctr/index.htm) under identifier UMIN000001706. HLA matching 
was evaluated with molecular typing. Patients with high serum creatinine levels and/or a 
lower estimated glomerular filtration rate greater than grade 2, and/or other organ 
dysfunctions greater than grade 3 defined by the Common Terminology Criteria ver.3.0 
for Adverse Events (CTCAE) of the National Cancer Institute, USA, were excluded. 
Regimens for preconditioning and prophylaxis for graft-versus-host disease (GVHD) 
were not specified. Peripheral blood samples were obtained every Monday, Wednesday, 
and Friday from day 6 to day 28 after BM transplantation (BMT) or peripheral blood 
stem cell transplantation (PBSCT) from unrelated donors or HLA-mismatched relatives 
and day 6 until day 35 after UCBT. Frozen plasma samples were sent to SRL, Inc 
(Tokyo, Japan) to measure the amount of HHV-6 DNA using a real-time quantitative 
PCR method the following day (5) (6). This system could detect both HHV-6 variant A 
and variant B, but it could not distinguish between them. Prophylactic administration of 
PFA at 90 mg/kg/day was started from day 7 and continued for 14 days after BMT or 
PBSCT and was administered from day 7 for 18 days after UCBT. In case HHV-6 
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DNAemia developed during the PFA administration, PFA was extended until HHV-6 
DNA became negative on 3 consecutive occasions. If a patient’s creatinine clearance 
fell below 1.4 ml/min/kg, the PFA dose was reduced according to the manufacturer’s 
instructions. The administration of other antiviral agents, such as acyclovir and GCV, 
was discontinued during the PFA administration period. AEs developing during the test 
period were evaluated by the CTCAE ver.3.0. The last 10 patients that received SCT by 
the end of March 2010 and met all of the criteria noted above except for PFA 
administration by day 35 after SCT, were selected as a control group for a matched-pair 
analysis to eliminate any possible bias. This group consisted of patients who were 
transplanted before and after the study period and those who refused to participate in the 
study. 
 
Definition of HHV-6 encephalitis 
The diagnosis of HHV-6 encephalitis was made by a neurologist based on a positive 
result for HHV-6 DNA in cerebrospinal fluid and the presence of neurologic symptoms 
such as paresthesia, confusion, seizure and consciousness disturbance (2). When 
cerebrospinal fluid was not available for the examination of HHV-6 DNA, the diagnosis 
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was made based on the findings compatible with limbic encephalitis according to the 
magnetic resonance (MR) imaging findings and the presence of HHV-6 DNAemia. 
 
Statistical analysis 
The following variables related to patients and their clinical data were compared among 
the groups using the Mann-Whitney U test: age, date of WBCs > 0.1  109/l, and date of 
neutrophils > 0.5  109/l. All P values were two-sided with values < 0.05 being 
considered statistically significant. These analyses were performed using JMP® ver. 7.0 




A total of 10 patients were enrolled this study. The characteristics of these patients and 
the 10 patients enrolled as the control group are summarized in Table 1; the median age 
of the tested patients was younger than the control patients (40 years for prophylactic 
PFA patients vs. 51 years for control patients), but there were no significant differences 
between the groups. The underlying disease in the prophylactic PFA patients were 6 
acute leukemias, 1 myelodysplastic syndrome (MDS) and 3 lymphomas, while there 
9 
 
were 5 acute leukemias, 2 MDS and 3 lymphomas in the patients of the control group. 
Approximately half of the patients had reached complete remission and received 
myeloablative conditioning prior to SCT in both of the groups. Most of the patients 
received BM grafts from an unrelated donor, except 2 SCT that were from mismatched 
siblings and 2 UCBT in the prophylactic PFA patients. Eight of the 10 patients in each 
group received cyclosporine for GVHD prophylaxis. 
 
Toxicities of prophylactic PFA administration 
Two patients dropped out of this study due to AEs; one patient died due to 
transplant-related complications (bacterial pneumonia) and another patient was grade 2 
low glomerular filtration rate. Two patients required dose reduction of PFA because of 
creatinine increase (grade 2 in 1 patient and grade 1 in 1 patient). AEs graded greater 
than 3 by CTCAE were observed in 9 of the 10 patients who received prophylactic PFA 
and in 7 of the 10 patients in the control group (Table 2). Noticeable AEs in 
prophylactic PFA patients were infection and cellulitis; mortal pneumonia in 1 patient, 
bacteremia in 2 patients, bacterial cystitis in 1 patient and viral cystitis in 1 patient. 
These AEs were improved, except for the grade 5 pneumonia, after appropriate therapy. 
Renal dysfunction, a characteristic AE caused by PFA, occurred less frequently in the 
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PFA patients (2 with grade 2) than in the control group (grade 4 in 1 patient and grade 2 
in 4 patients). The patient with grade 4 renal dysfunction developed uncontrollable 
aGVHD (grade 4) complicated by a critical infection, thus leading to the onset of 
drug-induced renal failure, due to the administration of antibiotics and cyclosporine. A 
non-infectious pulmonary complication (grade 3) developed in 1 PFA patient, who 
transiently required oxygen inhalation for 3 weeks and thus was withdrawn from the 
study. Of interest, disturbance of consciousness was not seen in any of the patients 
receiving prophylactic PFA administration, but was seen in 4 of the 10 patients in the 
control group, including 2 patients diagnosed with HHV-6 encephalitis. 
 
Clinical significance of prophylactic PFA administration and the development of 
HHV-6 DNAemia 
We have summarized the clinical information of the patients, dividing them into 2 
groups; patients who received prophylactic PFA administration and control patients 
(Table 3). No differences were observed between the 2 groups in terms of the period 
from SCT to achieving neutrophils > 0.5  109/l and WBCs > 0.1  109/l, and the 
development of acute GVHD. 
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 Of the 10 patients who received prophylactic PFA administration, 3 patients 
developed HHV-6 DNAemia between day 18 and day 23 after SCT. The highest 
HHV-6 DNA copy number in these 3 patients was 6.4 x 103/ml. Two of the 3 patients 
(UPN 102 and UPN 110) were detected to have HHV-6 DNA during PFA 
administration, and the PFA treatment was extended until HHV-6 DNA disappeared 
from their plasma (Figure 1a). The other patient (UPN109) was observed to have 
HHV-6 DNAemia 3 days after cessation of PFA, and the HHV-6 DNA disappeared in 4 
days with no additional PFA administration (Figure 1b). None of the patients who 
received prophylactic PFA administration developed neurological symptoms, thus 
suggesting the occurrence of HHV-6 encephalitis during the test period. However, 3 of 
4 control patients who experienced neurological symptoms were positive for HHV-6 
DNA in their plasma, including 2 patients diagnosed as having HHV-6 encephalitis 
(Table 3). The cerebrospinal fluid was examined in 2 of the 3 control patients who were 
positive for plasma HHV-6 DNA. One patient was positive (UPN C3) for HHV-6 DNA 
and the other was negative (UPN C15). 
 Figure 2 shows the MR images of a control patient (UPN C3) who developed 
limbic encephalitis; hallucination and short-term memory loss were observed on day 20, 
and a seizure following a coma occurred on day 22 after BMT. Only 1.2 x 102/ml of the 
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HHV-6 DNA was detected in the patient’s plasma on day 26, which thus indicates a 
diagnosis of HHV-6 encephalitis at that time. However, the MR images on day 27 
revealed symmetric enhancement of the limbic cortex on fluid-attenuated 
inversion-recovery (FLAIR) imaging (Figure 2A) and the positive result for HHV-6 
DNA in cerebrospinal fluid on day 28 indicated that the etiology of these neurologic 
symptoms was HHV-6 encephalitis. The level of consciousness and the MR findings of 
the patients slowly improved (Figure 2B), but the short-term memory loss remained. 
 
Discussion 
The results of an in vitro study showed that PFA and cidofovir were superior to GCV 
for the treatment of HHV-6 infection (7, 8). PFA was selected as an anti-HHV-6 agent 
because cidofovir was not authorized in Japan and PFA had lower BM toxicity than 
GCV (9). A few papers have so far been published regarding the safety and efficacy of 
PFA for cytomegalovirus infection after SCT (3) (10) (11). However, most of the 
patients enrolled in these studies were administered PFA around day 30 or later after 
SCT, and the investigators were unable to evaluate the influence of PFA on 
hematopoiesis before neutrophil engraftment. In contrast to GCV, PFA administration 
is not usually associated with BM suppression; however, it is possible that it may 
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impair hematopoietic stem cell engraftment when it is used soon after transplantation. 
In addition, the administration of PFA in the early SCT period with intensive 
multidrug therapy might cause more severe renal dysfunction than conventional use. 
The current study showed that administration of PFA had little impact on 
hematopoiesis after SCT, suggested by the equivalence of WBCs and neutrophil 
recovery between the treatment and control groups. Also, the number of patients who 
developed renal dysfunction and electrolyte abnormalities as AEs in the PFA-treated 
group was not higher than in the control group, although 2 patients needed dose 
reduction of PFA, thus indicating the safety of PFA administration during this period. 
We considered that the higher frequency of infectious events in PFA-treated patients 
compared to the untreated patients might have been caused by the differences in the 
graft source for SCT; the PFA-treated patients received HLA-mismatched grafts and 
UCB, while all of the untreated patients were grafted with BM from an unrelated 
donor. 
 Although many clinicians have recognized the risk of HHV-6 encephalitis, 
strategy for preventing HHV-6 encephalitis have not been established. Two previous 
reports showed the efficacy of prophylactic GCV from the time of neutrophil 
engraftment (12) (13); but only 1 UCBT recipient was included in this study. Ogata et 
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al. has documented that a preemptive approach consisting of HHV-6 DNA 
measurement in peripheral blood once a week and starting PFA administration in cases 
where the HHV-6 DNA exceeded 1.0 x104/ml was insufficient (14). Our previous 
study, consisting of HHV-6 DNA measurement in peripheral blood three times per 
week from day 7 after SCT and starting PFA administration when the amount of 
HHV-6 DNA increased to greater than 5 x 102/ml, also failed to prevent encephalitis, 
and it was concluded that prophylactic PFA administration from day 7 or earlier until 
day 20 after SCT would be necessary (4). The current results shows that the 90 mg/kg 
dose of prophylactic PFA beginning from day 7 after SCT is safe with tolerable AEs, 
and that it could be effective for the prevention of HHV-6 encephalitis. The 
development of HHV-6 DNAemia could not be entirely prevented, but all 3 positive 
cases had less than 1.0 x105/ml of HHV-6 DNA, a level that indicates the development 
of limbic encephalitis (15). Therefore, these levels of HHV-6 DNA observed in 
patients who received PFA prophylaxis, which were lower than described in previous 
reports, might therefore reflect the efficacy of prophylactic PFA administration. 
Meanwhile, 1 of the 2 control patients who developed limbic encephalitis showed a 
significantly high copy number of HHV-6 DNA (> 1.0 x105/ml), which was 
characteristic of HHV-6 encephalitis; however, the other case showed only 1.2 x 
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102/ml of HHV-6 DNA in his plasma. These two cases may differ due to the timing of 
the examination of HHV-6 DNA, because the HHV-6 DNA copy number dramatically 
changed within a couple of days (4, 15) . The current study examined the plasma 
HHV-6 just after the appearance of the initial neurologic symptoms in the former case, 
but 6 days after the initial symptoms in the latter case, which may have missed the 
peak of the HHV-6 DNA. 
 In the current study, the reactivation of HHV-6 occurs around the time of 
neutrophil engraftment; however, all 3 PFA-treated cases positive for HHV-6 DNA in 
the plasma developed on and after neutrophil engraftment, despite the fact that 5 of 7 
UCBT patients developed HHV-6 DNAemia on and before neutrophil engraftment in 
our previous study. These results suggest that the prophylactic PFA administration 
may delay the development of HHV-6 DNAemia for a few days, signifying that its 
development is avoided in the early period after SCT, which might lead to decreased 
transplant-related mortality. 
 The current study was a small trial designed to evaluate the safety of 
prophylactic PFA administration early after SCT before neutrophil engraftment. The 
results achieved the primary endpoint. This strategy may reduce the risk of limbic 
encephalitis, though it may not be able to entirely prevent HHV-6 reactivation. 
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Although our present study failed to establish sufficient clinical evidence because of 
the shortage of cases, our results are thus considered to provide the basis for the design 
of a large-scale prospective study with many patients, to compare the efficacy and 
safety between preemptive therapy and prophylactic therapy by PFA, to prevent 
HHV-6 disease in allo-SCT recipients. 
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Figure legends 
Figure 1. Development of HHV-6 DNAemia in patients during (a, UPN 102) and after 
(b, UPN 109) PFA administration. The columns represent copy numbers of HHV-6. 
WBC, white blood cell count; PFA, phosphonoformic acid (foscarnet). 
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Figure 2. Magnetic resonance images of the brain of the patient who developed limbic 
encephalitis (UPN C3). Both of the images were taken by fluid-attenuated 
inversion-recovery (FLAIR) at the level of the basal ganglia. A; day 27 after SCT, B; 
day 38 after SCT. 






